Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J. Pineal Res. 2000; 2:100 -107. © Munksgaard, Copenhagen Abstract: Degeneration of nigrostriatal dopaminergic neurons is the major pathogenic substrate of Parkinson's disease (PD). Inhibitors of monoamine oxidase B (MAO-B) have been used in the treatment of PD and at least one of them, i.e., deprenyl, also displays antioxidant activity. Dopamine (DA) autoxidation produces reactive oxygen species implicated in the loss of dopaminergic neurons in the nigrostriatal pathway. In this study we compared the effects of melatonin with those of deprenyl and vitamins E and C in preventing the hydroxyl radical ( OH) generation during DA oxidation. The rate of production of 2,3-dihydroxybenzoate (2,3-DHBA) in the presence of salicylate, an OH scavenger, was used to detect the in vitro generation of OH during iron-catalyzed oxidation of DA. The results showed a dose-dependent effect of melatonin, deprenyl and vitamin E in counteracting DA autoxidation, whereas vitamin C had no effect. Comparative analyses between the effect of these antioxidants showed that the protective effect of melatonin against DA autoxidation was significantly higher than that of the other compounds tested. Also, when melatonin plus deprenyl were added to the incubation medium, a potentiation of the antioxidant effect was found. These findings suggest that antioxidants may be useful in brain protection against toxicity of reactive oxygen species produced during DA oxidation, and melatonin, alone or in combination with deprenyl, may be an important component of the brain's antioxidant defenses to protect it from dopaminergic neurodegeneration.
Introduction
Dopamine (DA) is a neurotransmitter with important functions in cognitive and motor processes. Accumulating evidence suggests that DA may also serve as a neurotoxin and, as a result, it may participate in neurodegenerative processes [Luo et al., 1998 ] such as in Parkinson's disease (PD). The mechanism of DA toxicity is linked to its oxidative metabolism [Chuang et al., 1993] . DA contains an unstable catechol, which can be either metabolized enzymatically via a monoamine oxidase (MAO)-catalyzed reaction or it can oxidized spontaneously to form reactive oxygen species and quinones [Chuang et al., 1993; Kondo, 1996; Aguilar et al., 1998 ]. These oxidative products can damage neurons via denaturation of proteins, injury to DNA and to the cell membrane. Although the cause of age-related degeneration of dopaminergic neurons in PD is not established, it is believed that the oxidative stress induced by DA is a major physiopathological factor. Recent studies have shown that iron enhances the toxicity of DA by increasing its rate of non-enzymatic oxidation [Velez Pardo et al., 1997] . The caudate putamen, nucleus accumbens, and substantia nigra are the brain regions most likely to generate cytotoxic free radicals due of their high levels of DA and iron. Therefore, the production of DA by neurons presumably exposes them to DA-derived cytotoxic compounds including free radicals, leading to a loss of a critical number of cells and hence clinical disease.
The 1-methyl-4-phenylpiridinium ion (MPP + ), a cytotoxic metabolite produced by the action of monoamine oxidase B (MAO-B) on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces a sustained, massive DA overflow in the striatum, leading to extraneuronal autoxidation of released DA and subsequent free radical generation [Chuang et al., 1992] . Besides the inhibition of mitochondrial respiratory complex I by MPP + itself, the production of free radicals induced by the neurotoxin seems to be an important factor in the development of PD induced by MPTP. Thus, it is important to reduce DA-dependent free radical formation to protect dopaminergic neurons from degeneration. MPTP-induced PD may be partially counteracted by MAO B inhibitors such as deprenyl. It is now recognized that, besides its enzymatic inhibitory effect, part of the neuroprotective effects of deprenyl are due to its antioxidant action and its upregulation of antioxidant enzymes [Chiueh et al., 1994; Kitani et al., 1996] .
Increasing evidence for the antioxidant and free radical scavenging properties of melatonin is now available [Reiter, 1995; Reiter et al., 1995; Acuña-Castroviejo et al., 1995] . In vitro studies have shown that melatonin is a more efficient quencher of OH than the two well-known free radical scavengers glutathione and mannitol [Tan et al., 1993 [Tan et al., , 1998 Reiter et al., 1994a,b] . Besides, melatonin may also stimulate enzymes involved in redox reactions that reduce free radical production such as glutathione peroxidase Pablos et al., 1995; Kotler et al., 1998 ]. Thus, not only is melatonin a scavenger of OH, but it promotes the production of a second molecule, which is known to provide intracellular protection against free radicals. A variety of experiments have also confirmed that melatonin limits free radical damage in organisms in vivo Melchiorri et al., 1995b; Mayo et al., 1998; Princ et al., 1998; Crespo et al., 1999] . In these experiments, both pharmacological and physiological levels of melatonin were effective in protecting cells (including DNA and cytosolic proteins) from free radical damage. Thus, through its antioxidant properties, melatonin behaves as a prophylactic hormone against free radical damage in the brain [Melchiorri et al., 1995a; Reiter et al., 1997; Reiter, 1998 ].
In the present study, we compared the antioxidant activity of melatonin with that of deprenyl and vitamins E and C on DA autoxidation. The objective of this study was to test the ability of these compounds to prevent OH generation during iron-catalyzed oxidation of DA in vitro.
Materials and methods

Chemicals
All reagents used were of the highest purity available. DA, sodium salicylate, ferrous sulfate, ascorbate and 2,3-dihydroxybenzoic acid (2,3-DHBA) were purchased from Sigma Química (Spain). Trolox was obtained from Fluka (Sigma) and Ldeprenyl was obtained from RBI (Sigma).
Assay conditions
Oxidation of DA was done as described elsewhere [Chiueh et al., 1992] . Briefly, OH were generated by incubating 1 mL Ringer solution (pH 7) containing 1 mM DA and 50 mM FeSO 4 at 37°C in darkness under continuous oxygenation. Melatonin, deprenyl, Trolox (a soluble form of vitamin E), and ascorbate were added to the incubation medium at different concentrations ranging from 1 to 1000 mM. Incubations were done at 24, 48, 72 and 96 hr and the OH generated was determined according to the salicylate trapping procedure [Barry et al., 1991] . This method is based on the ability of OH to react with salicylate generating two main products, 2,3-and 2,5-DHBA, respectively). However, according to previous reports and our own results, 2,3-DHBA is a more reliable indicator of OH generation than is 2,5-DHBA [Halliwell et al., 1991] . Thus, only the amount of 2,3-DHBA formed in the incubation medium was measured.
Sample analysis
Immediately after the incubation period, an aliquot of the reaction mixture was diluted in 0.2 M perchloric acid, and stored at −80°C until analysis. Aliquots of the samples were analyzed by high-performance liquid chromatography with electrochemical detection (HPLC-ED) to measure their content in 2,3-DHBA. The detector potential was set at +0.8 V using a glass carbon electrode versus an Ag AgCl reference electrode. The mobile phase contained 50 mM sodium acetate, 50 mM citric acid, 0.4 mM sodium octyl sulfate, 1.1 mM n-dibutyl amine, 0.15 mM EDTA and 5% (vol/vol) methanol/water. The solution was filtered through a 0.45 mm filter and degassed before use. Analyses were done under isocratic mode, at a flow rate of 1 mL/min at room temperature. The concentration of 2,3-DHBA in the analyzed sam-ples was calculated with the aid of a calibration curve obtained after standards injection in the HPLC system.
Statistical analyses
Data are expressed as mean 9SEM. In order to achieve the goals of the study, a factorial design analysis was carried out. The factorial design had three fixed effect factors: Time (four levels, i.e., 24, 48, 72 and 96 hr), drug (five levels, i.e., melatonin, deprenyl, Trolox, ascorbate and deprenyl + melatonin) and dose (five levels, i.e., 0, 1, 10, 100 and 1000 M), having 3 -5 replicates in the crossing of the three factors. Second order interaction (time× drug× dose) was significant and so a pairwise comparison between the levels of one factor and the levels of the other was carried out. Pairwise comparisons were done using Bonferroni's method. The general Linear Model program SPSS 8.0 was used. Table 1 shows the time-and dose-dependent production of 2,3-DHBA due to in vitro DA autoxidation in the presence of Fe 2 + and salicylate, reflecting OH formation. Control groups of DA autoxidation correspond to those in which drug concentration is zero. At time zero, no production of 2,3-DHBA was detected, and it increased with the incubation time. The addition of melatonin significantly decreased the production of 2,3-DHBA, the effect being significant at a dose of 10 mM after 24-96 hr of incubation. When the concentration of melatonin in the incubation medium increased, the production of 2,3-DHBA decreased significantly in a dose-dependent manner and thus, melatonin significantly reduced the production of 2,3-DHBA at all time-points (Table 1) . A similar concentration dependency on 2,3-DHBA production was noted after deprenyl (Fig. 1b) or Trolox (Fig. 1c) addition. In the case of deprenyl, the reduction of 2,3-DHBA production was significant at a dose of 100 mM in all time-points (Table 1) . When Trolox was added to the incubation medium, a significant reduction in 2,3-DHBA production was found at 10 mM at all time-points (Table 1) . Although Trolox is a water-soluble vitamin E analog, it was not possible to solubilize Trolox above 100 mM in our incubation medium and thus, it was not possible to evaluate the effect of 1000 mM Trolox on DA autoxidation. In the case of ascorbate, no significant reduction in 2,3-DHBA levels was observed (Table 1) . Fig. 1 shows the percentage of 2,3-DHBA produced during DA autoxidation in the presence of each drug tested at different times of incubation. Statistical analysis revealed that after 24 hr of incubation, 100 mM melatonin was significantly more efficient than deprenyl or Trolox in inhibiting DA oxidation. Also, at 48, 72 and 96 hr of incubation, the antioxidant effect of melatonin increased and thus, at 10 mM the indoleamine was significantly stronger than deprenyl or Trolox in reducing DA oxidation (Fig. 1) . In our experimental model, ascorbate had no antioxidant activity and at 100 and 1000 mM this compound behaved as a weak pro-oxidant (Fig. 1) .
Results
To study any interaction between melatonin and deprenyl, both compounds were incubated together with DA and the production of 2,3-DHBA was measured. Fig. 2 represents the percentage of 2,3-DHBA produced during DA autoxidation in the presence of deprenyl or deprenyl+melatonin. It can be seen that the production of 2,3-DHBA was significantly lower at 96 than at 72 hr of incubation in the presence of 100 mM melatonin plus 1000 mM deprenyl, and this effect was significantly different from 10 mM melatonin+1000 mM deprenyl.
Discussion
In this paper we show that melatonin counteracts OH produced during DA autoxidation in vitro. We also shown that deprenyl displays OH scavenging properties, providing for another neuroprotective role of this compound in addition to its MAO-B inhibitory activity. Conversely, vitamin E was less potent than melatonin in this experimental paradigm, whereas ascorbate failed to act as scavenger against DA-autoxidation as reported earlier [Chiueh et al., 1994] .
The nonenzymatic oxidation of DA is known to be catalyzed by oxygen and transition metals, such as Fe 2 + . In addition to the formation of semiquinone radicals and melanin, in vivo DA autoxidation leads to the production of cytotoxic OH in iron-rich basal ganglia [Chiueh et al., 1992] (Fig. 3) . Many different assays have been used to estimate the highly-reactive OH generated in biological systems. Among these methods, the interaction of OH with salicylate (2-hydroxybenzoate) generates 2,3-and 2,5-DHBA as major products [Moorhouse et al., 1985] . It was therefore suggested that formation of these two compounds might be a sensitive assay for OH formation both in vitro and in vivo. In fact, several methods including intracranial microdialysis of salicylate have been used to detect OH generated through DA autoxidation in vivo [Chiueh et al., 1992] . However, it was noted that 2,5-DHBA may also be produced in vivo by an enzymatic system such as the cytochrome P-450 system in humans and other mammals. Thus, measurement of 2,5-DHBA may provide misleading results [Halliwell et al., 1991] . Although this is not applicable to our in vitro conditions, we decided to measure only 2,3-DHBA, because measurements of 2,5-DHBA in our conditions were more variable than those of 2,3-DHBA.
Antioxidant and neuroprotective properties of melatonin have been reported Reiter et al., 1997; Reiter, 1998 ] and they include its ability to rescue culture cells from oxidative stress [Iacovitti et al., 1997] and to inhibit oxidative damage in a variety of neurodegenerative models such as PD, Alzheimer and kainate-induced excitotoxicity, in which free radicals have been implicated [Giusti et al., 1996 ; Acuñ a-Castroviejo et al., 1997; Brusco et al., 1998; Mayo et al., 1998; Pappolla et al., 1998 ]. Studies in vitro and in vivo have shown that melatonin scavenges OH, which may be relevant to its biological action [Tan et al., 1993 [Tan et al., , 1998 Matuszak et al., 1997] . In a previous report, it was demonstrated that melatonin at a dose of 10 mM significantly reduced DA autoxidation as assessed in vitro using the oxygen radical absorbance capacity assay [Miller et al., 1996] . The decrease in OH generated by in vitro DA autoxidation, as described here, further demonstrates the protection of melatonin against catecholamine autoxidation. It is interesting to note that the O 2 − produced during oxygen-induced DA oxidation may oxidizes another DA molecule and so, DA acts as scavenger of O 2 − . However, this feature of DA is ineffective because after reacting with DA, O 2 − becomes H 2 O 2 that, in the presence of Fe 2 + , yields OH through the Fenton reaction (Fig. 3) . A different mechanism involves the antioxidant properties of melatonin. Melatonin detoxifies OH by electron donation [Tan et al., 1993] . In doing so, it becomes the melatonyl cation radical which in turn interacts with O 2 − to form the stable end product N-acetyl-N-formyl-5-methoxykynuremine (Fig. 3) . A recently proposed reaction pathway suggests the production of cyclic 3-hydroxymelatonin after scavenging two OH molecules with one of mela- the suppression of both intraneuronal hydrogen peroxide formation produced by MAO oxidation of cytosomal DA and extraneuronal free radical generation caused by the autoxidation of released DA [Wu et al., 1996] .
Trolox, a water soluble vitamin E analog and known antioxidant [Forrest et al., 1994] , also scavenged OH produced by DA autoxidation in vitro, although it was less potent than melatonin. This result, together with data published elsewhere [Marchiafava and Longoni, 1999] , support the idea that melatonin is a more powerful OH scavenger than vitamin E in vitro. However, the vitatonin [Tan et al., 1998 ]. The present results are consistent with in vivo studies showing a neuroprotection by melatonin against MPTP-induced nigrostriatal degeneration . Thus, it seems that the neuroprotection elicited by melatonin is due, at least in part, to the suppression of site-specific generation of cytotoxic OH during the oxidation of released DA in the striatum.
In the present in vitro study, we demonstrated that 2,3-DHBA formation through DA autoxidation is also suppressed by the MAO-B inhibitor deprenyl, reflecting a reduction in OH generation by the drug. The antioxidant effect of deprenyl is comparable with that of melatonin, an OH scavenger [Chiueh et al., 1993] . Therefore, deprenyl (and other propargyl MAO inhibitors) inhibit not only enzymatic oxidation, but also nonenzymatic oxidation of DA [Chiueh et al., 1994] . Deprenyl may prevent oxidative damage to nigral neurons caused by free radicals produced in situ through min E in the membrane of neurons may help to counteract lipid peroxidation induced by free radicals generated through DA oxidation in vivo [Forrest et al., 1994] . Another antioxidant vitamin, ascorbate, was however unable to counteract DA autoxidation under our in vitro conditions. Conversely, by increasing the concentration of ascorbate there was a progressive enhancement of OH formation. The pro-oxidant effect of ascorbate is best explained by its involvement in the reduction and redox recycling of iron from Fe 3 + to Fe 2 + states [Gotz et al., 1994] , with subsequent effects mediated by the enhanced production of H 2 O 2 . The ascorbate radical generated by the one-electron oxidation of this reduced compound, promotes additional oxyradical by reacting with oxygen forming O 2 − (Fig. 3) . Thus, the pro-oxidant/anti-oxidant properties of ascorbate are extremely complex, and its in vivo behavior, where it seems to exert neuroprotective activity [Desole et al., 1993] , may depend on its intracellular concentration and also on its intracellular free iron content. It is important to note that the pro-oxidant activities of ascorbate and DA use different pathways: While ascorbate reduces and recycles iron providing both H 2 O 2 and catalytic Fe 2 + for augmented OH production by the Fenton reaction, the enhanced production of OH by DA results from its oxidation either by molecular oxygen or Fe 3 + , with the subsequent formation of semiquinones, O 2 − and H 2 O 2 [Nappi and Vass, 1997] .
These antioxidant effects of melatonin, deprenyl and Trolox in vitro may be of importance under in vivo conditions. MPTP-treated mice develop a Parkinsonism-like neurodegenerative condition that is very useful for the study of the physiopathology and preventive treatments for PD. In mice treated with deprenyl before MPTP administration, striatal DA depletion elicited by the neurotoxin is prevented [Gupta and Weiner, 1995] . Melatonin administration to MPTP-treated mice prevents the induction of Parkinson-like signs . Thus, melatonin, through its antioxidant role and deprenyl, due to its antioxidant and MAO-B inhibitory effects [Chiueh et al., 1994] , exerts protective effects in MPTP-induced PD. These data suggest that the use of combination drug therapy (i.e., melatonin+deprenyl) may be useful in the treatment of PD. The combination therapy may be important since we found a potentiating effect of melatonin plus deprenyl treatment in counteracting OH production in our system, suggesting that the effect of these drugs together was significantly higher than the effect of each drug separately.
These data suggest a possible degree of co-operativity between the drugs in vivo. In fact, studies from our laboratory have shown that the effect of a small dose of deprenyl in MPTP-treated mice was significantly improved by the simultaneous administration of melatonin in a dose-dependent manner (unpublished data).
The present study shows that melatonin and deprenyl strongly attenuate OH formation during DA oxidation in vitro, suggesting that the indoleamine is an important cellular antioxidant. In turn, the age-dependent decline in melatonin production [Reiter, 1992] may be implicated in the age-related dopaminergic neurodegenerative disorders, such as PD. Our results also support recent findings implicating ascorbate and DA as contributing factors in the enhancement of iron-mediated oxidative processes that generate the highly cytotoxic OH [Nappi and Vass, 1997] . From these data two main considerations may arise: First, neuroprotective therapeutics with melatonin may be useful in slowing or halting the progression of neurodegenerative processes in some neurodegenerative disorders including aging itself; second, the use of certain therapeutics involving antioxidants such as ascorbate should be revised.
